ClinicalTrials.gg
CompletedNCT06533657UTOPIA-1Updated Sep 1, 2026

Unique Treatment of Oncology Pain in Advanced Cancer

A Phase 2 interventional study of Trichomylin® capsule (5 mg delta-9-tetrahydrocannabinol: 5 mg cannabidiol: 5 mg cannabichromene) in Cancer Pain, sponsored by ZYUS Life Sciences Inc.. Completed at 3 sites in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-01.

Sponsored by ZYUS Life Sciences Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
11
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies in Cancer Pain with a site in Canada — 1 open to participants now, 1 under way, none of them phase 3. Cancer Pain · Canada.

Started
2025
the only one that year
Phase 2
2 of 10
none open now
Registered
10th of 10
by date
Lead sponsor
1 of 10
ZYUS Life Sciences Inc.

Among the 10 studies in Cancer Pain with a site in Canada, this one is the only one that started in 2025, is one of 2 in phase 2, and was the 10th registered.

Cancer Pain

311 studies on the registry are indexed under Cancer Pain; 74 are open to participants now.

Browse Cancer Pain studies →

Open to participants now

1 of the 10 studies in Cancer Pain with a site in Canada is open now. Recruiting first, the newest first:

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 44 Cancer Pain studies recruiting now, 32 (73%) set no upper age limit and 4 (9%) stop at 75 or younger; 4 take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Cancer Pain with a site in Canada, or all of them as a file.
02

Study summary

This will be a proof-of-concept, single arm study with a maximum of 20 patients to evaluate preliminary analgesic efficacy and safety of Trichomylin® in patients with advanced cancer (male and female) who suffer from moderate to severe chronic pain and who are taking a stable dose of long-acting opioid therapy for at least 1 week prior to screening.

Read the detailed description

This study will consist of a screening visit, treatment, and safety follow-up period. There will be an initial patient determined titration phase, using escalated doses of Investigational Product, to reach a dose that achieves symptom relief with tolerable side effects. Each capsule of Trichomylin® contains a fixed ratio of 5 mg delta-9-tetrahydrocannabinol: 5 mg cannabidiol: 5 mg cannabichromene. Participants can titrate up to a maximum of 2 capsules twice daily (total of 4 capsules). This will be followed by a 5 day assessment period of the stable dose determined in collaboration with clinicians.

03

Conditions studied

  • Cancer Pain

Browse trials for

Keywords

  • Cannabinoid
  • Safety and Tolerability
  • Preliminary Efficacy
  • Opioid-sparing
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participant has voluntarily agreed to study participation by giving written and must be ≥18 years of age on the day of signing the informed consent form (ICF).
  2. Participant has advanced solid malignant tumors not amenable to curative-intent therapy (locally advanced unresectable or ).
  3. Participant is ≥3 months at screening according to investigator's best judgement.
  4. Participant has a clinical diagnosis of moderate to severe cancer-related pain with average daily pain score to be ≥4 for at least 4 out of the 7-day screening period, despite ongoing opioid treatment, as evidenced by their response to the BPI-SF Question #5 on the Numeric Rating Scale (NRS).
  5. Participant is taking a stable dose of opioid therapy (Step III according to the World Health Organization [WHO] analgesic ladder) for at least 1 week prior to screening to relieve cancer-related pain.
  6. Participant has adequate organ function, as indicated by the following laboratory values, at screening:

    1. Baseline serum electrolytes must be within the normal range per local laboratories (for baseline serum electrolytes that are out of range, these may be corrected, and the potential participant may be rescreened).
    2. Stable renal function (estimated [eGFR] >15).
    3. Total (TBIL) ≤1.5 x (ULN); or ≤3 x ULN for participants with Gilbert's syndrome.
    4. (AST) and alanine aminotransferase (ALT) ≤3 x ULN or ≤5 x ULN for participants with liver metastases.
  7. Participant has stable cardiac function, as determined by:

    1. No waveform abnormalities.
    2. corrected for heart rate using Fridericia's formula (QTcF) ≤470 msec, as determined by the mean QTcF values from the ECG assessments at screening (one triplicate).
  8. Participant can tolerate oral medications including capsules.
  9. Participant is willing to take a medication which may exhibit psychoactive effects.
  10. Participant must discontinue the use of the following medications 7 days before the start of study intervention and for the duration of the trial, unless in the opinion of the investigator and sponsor, the medication will not interfere with the study: herbal supplements or related products which are cytochrome P450 (CYP) 2E1, , or P-glycoprotein substrates, or which are strong inhibitors of the CYP3A4 and/or CYP3A5 pathways or which are known CYP3A4 inducers (this includes grapefruit and Seville oranges juice or related products, and St. John's wort).
  11. Participant must not engage in medicinal or recreational use of any cannabinoid containing substance, in any form, within 30 days prior to screening and be willing to abstain from medicinal or recreational use of cannabis and other cannabinoid compounds (other than the Product) for the duration of the study.
  12. Participant must have a negative urine drug screen for cannabinoids at screening and prior to dosing at Day 1; one repeat test may be conducted for a suspected false positive result.
  13. Participant must not have any current or past allergic or adverse reaction or known sensitivity to olive oil, gelatine, glycerin, and titanium dioxide, or to cannabinoid-like substances (including but not limited to dronabinol, marinol, nabilone, marijuana, cannabis, THC, or cannabinoid oil).
  14. Female participants are eligible to enter and participate in the study if they are of:

    1. Non-.
    2. Childbearing potential with a negative serum pregnancy test at screening (within 7 days of the first dose of Investigational Product) and agree to use before study entry and throughout the study until 3 months after the last administered dose of the Investigational Product.
  15. Male participants are eligible to enter and participate in the study if they are vasectomized or agree to the use of contraception during the study treatment period and for at least 3 months after the last administered dose of the Investigational Product.
  16. Participants, in the opinion of the investigator, should understand the nature of the study, be able to participate in all planned assessments, complete all required tests, and be likely to comply with all study procedures.

Exclusion criteria

Exclusion Criteria:

  1. Female participants who are pregnant or lactating.
  2. Participant has uncontrolled psychiatric disorders (severe depression or anxiety, personality disorder, psychosis, or schizophrenia).
  3. Participant has a family history of schizophrenia.
  4. Participant has current or history of suicidal behavior or ideation assessed by Columbia-Suicide Severity Rating Scale (C-SSRS).
  5. Participant has any known or suspected history of a diagnosed dependency disorder, including opioid abuse, current heavy alcohol consumption (i.e. more than 10 units of alcohol per week or 4 units on any given day [1 unit = 150 mL of wine, 260 mL of beer, or 45 mL of 40% alcohol]), current use of an illicit drug or current non-prescribed use of any prescription drug (Alcohol, Smoking and Substance Involvement Screening Test [ASSIST]).
  6. Participant has engaged in medicinal or recreational use of any cannabinoid containing substance, in any form within the 30 days prior to screening.
  7. Participant is within the first cycle of a new line of anticancer therapy (including but not limited to chemotherapy or other systemic anticancer therapies, immunotherapy, radiation therapy, or surgery) at the start of the screening period.
  8. Participant has had any major surgery within 4 weeks prior to screening.
  9. Participant has an active infection requiring systemic treatment at the start of the study treatment.
  10. Participant has cirrhosis or severe hepatic impairment defined as and ALT >3 x or >5 x ULN for participants with liver .
  11. Participant has any of the following cardiovascular criteria:

    a. Current evidence of unstable angina or another form of symptomatic cardiac ischemia b. Acute myocardial infarction ≤3 months prior to screening c. Heart failure of Classification III or IV ≤3 months prior to screening d. Grade ≥2 ventricular arrhythmia ≤3 months prior to screening e. Cerebrovascular Accident (CVA) or Grade ≥2 (TIA) ≤6 months prior to screening f. Grade ≥2 hypertension that cannot be managed by standard anti-hypertension medications before initiation of treatment g. Syncope or seizure ≤3 months before screening.

  12. Participant has a history or presence of gastrointestinal disease or other condition known to interfere with the absorption of drugs.
  13. Participant has intractable vomiting.
  14. Participant has any other condition or abnormality that, in the investigator's judgement after medical interview, physical examination, and/or screening and baseline investigations, renders participant unfit for the study or precludes the participant's safe participation in and completion of the study.
  15. Participant has concurrent participation in another therapeutic clinical trial or participation in another clinical trial within 30 days prior to the enrolment in this trial.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
11 participants (actual)

Study arms

  • Experimental
    Trichomylin®

    Trichomylin® capsule (5 mg delta-9-tetrahydrocannabinol: 5 mg cannabidiol: 5 mg cannabichromene)

    Drug: Trichomylin® capsule (5 mg delta-9-tetrahydrocannabinol: 5 mg cannabidiol: 5 mg cannabichromene)

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants That Reach the Stable Dose during Dose Titration

    Investigational Product will be titrated up incrementally until participants achieve their "optimal dose" that achieves symptom relief with tolerable side effects or to a maximum of 2 capsules twice daily. Once participants have had 2 full days (at minimum) of treatment at this dosage, this will then be considered their "stable dose".

    Time frame: Baseline (i.e. Day 1 Dose Titration) and Stable Dose Day 1, up to 14 days

  2. Change in Average Pain Scores from Baseline to Investigational Product Discontinuation

    The Brief Pain Inventory Short Form (BPI-SF) is a standardized scale used for capturing participant reported symptom assessments related to pain severity and the resulting functional interference caused by pain. The BPI-SF has a numerical rating scale used by participants to indicate their level of pain. Participants are asked to assign a number that best describes their pain on average from 0 = no pain, to 10 = pain as bad as you can imagine, at the same time every day during the Screening period (Day -7 to Day -1) and enter this number in response to the BPI-SF Question #5 on the evaluation form.

    Time frame: Baseline and Investigational Product Discontinuation, up to 23 days

  3. Proportion of Responders to Average Pain from Baseline to Investigational Product Discontinuation

    Average pain as entered in response to the BPI-SF Question #5, where response is defined as having a baseline of ≥30% from baseline at the Investigational Product discontinuation visit.

    Time frame: Baseline and Investigational Product Discontinuation, up to 23 days

  4. Number of Participants That Reach the Stable Dose during Dose Titration and Respond to Average Pain from Baseline to Investigational Product Discontinuation

    Participants have reached their "stable dose" and respond to average pain as entered in response to the BPI-SF Question #5, where response is defined as having a baseline of ≥30% from baseline at the Investigational Product discontinuation visit.

    Time frame: Baseline and Investigational Product Discontinuation, up to 23 days

  5. Change in Average Pain from Baseline to End of the Titration

    Average pain as entered in response to the BPI-SF Question #5.

    Time frame: Baseline and End of Dose Titration, up to 14 days

  6. Change in Pain Interference from Baseline to End of the Titration

    Pain interference is scored as the mean of the seven interference items and entered in response to the BPI-SF Question #9.

    Time frame: Baseline and End of DoseTitration, up to 14 days

  7. Change in Pain Interference from Baseline to Investigational Product Discontinuation

    Pain interference as entered in response to the BPI-SF Question #9.

    Time frame: Baseline and Investigational Product Discontinuation, up to 23 days

Secondary outcomes

  1. Incidence of Treatment Emergent Adverse Events

    The severity of an adverse events (AE) is graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) v5.0 (NCI 2017). The incidence of AEs will be presented as the number (percentage) of participants with treatment emergent adverse events (TEAEs) by system organ class and Preferred Term using the most current Medical Dictionary for Regulatory Activities (MedDRA) available at the time of study commencement.

    Time frame: Baseline and End of Safety Follow-Up, up to 56 days

  2. Incidence of Serious Adverse Events

    The incidence of serious adverse events (SAE) will be presented as the number (percentage) of participants with SAEs by system organ class and Preferred Term using the most current Medical Dictionary for Regulatory Activities (MedDRA) available at the time of study commencement.

    Time frame: Baseline and End of Safety Follow-Up, up to 56 days

  3. Incidence of Adverse Events of Special Interest

    The incidence of adverse events of special interest (AESI) will be presented as the number (percentage) of participants with AESIs by system organ class and Preferred Term using the most current Medical Dictionary for Regulatory Activities (MedDRA) available at the time of study commencement.

    Time frame: Baseline and End of Safety Follow-Up, up to 56 days

  4. Incidence of Adverse Events leading to Discontinuation of Study Treatment

    The incidence of adverse events (AE) leading to discontinuation of study treatment will be presented as the number (percentage) of participants with AEs by system organ class and Preferred Term using the most current Medical Dictionary for Regulatory Activities (MedDRA) available at the time of study commencement.

    Time frame: Baseline and End of Safety Follow-Up, up to 56 days

  5. Change in Electrocardiogram From Baseline to Investigational Product Discontinuation

    A triplicate 12-lead electrocardiogram (ECG) will be obtained using an ECG machine that automatically calculates the heart rate and measures PR, QRS, QT, and \[QTc\] intervals.

    Time frame: Baseline and Investigational Product Discontinuation, up to 23 days

  6. Change in Brief Pain Inventory Short Form from Baseline to Investigational Product Discontinuation

    The BPI-SF is a standardized scale used for capturing participant reported symptom assessments related to pain severity and the resulting functional interference caused by pain. The BPI-SF has a numerical rating scale used by participants to indicate their level of pain.

    Time frame: Baseline and Investigational Product Discontinuation, up to 23 days

  7. Proportion of responders in Brief Pain Inventory Short Form from Baseline to Investigational Product Discontinuation

    The BPI-SF is a standardized scale used for capturing participant reported symptom assessments related to pain severity and the resulting functional interference caused by pain. The BPI-SF has a numerical rating scale used by participants to indicate their level of pain. Response is defined as having a decrease in pain from baseline by ≥30% at the Investigational Product discontinuation visit.

    Time frame: Baseline and Investigational Product Discontinuation, up to 23 days

  8. Change in Depression, Anxiety and Stress Scale - 21 Items from Baseline to Investigational Product Discontinuation

    The Depression, Anxiety and Stress Scale- 21 Items (DASS-21) is a set of three self-report scales designed to measure the emotional states of depression, anxiety and stress. By examining these subscales separately, DASS-21 provides a comprehensive picture of an individual's emotional state, aiding therapists, and researchers in identifying the primary areas of concern.

    Time frame: Baseline and Investigational Product Discontinuation, up to 23 days

  9. Change in Quality of Life and Functional Status from Baseline to Investigational Product Discontinuation

    The European Organization for Research and Treatment of Cancer core Quality of Life (EORTC QLQ-C30) is designed to measure cancer patients' physical, psychological, and social functions. The questionnaire is composed of multi-item scales and single items (Version 3.0).

    Time frame: Baseline and Investigational Product Discontinuation, up to 23 days

  10. Change in Subjective Measures of Symptom Change from Baseline to Investigational Product Discontinuation

    The Patient Global Impression of Change (PGIC) is a subjective measure of symptom change. Participants rate their change on a 7-point scale that ranges from "very much improved" to "very much worse", with "no-change" as the mid-point.

    Time frame: Baseline and Investigational Product Discontinuation, up to 23 days

  11. Use of Oral Morphine Equivalents from Baseline to Investigational Product Discontinuation

    Rescue analgesia requirements, specifically use of opioid medications, both prescription and over the counter (OTC), will be documented at baseline and for the duration of the study. Opioid medications will be converted to morphine equivalent doses (MEDD) for comparison and evaluation purposes.

    Time frame: Baseline and Investigational Product Discontinuation, up to 23 days

07

Study locations

3 sites
  • CancerCare Manitoba
    Winnipeg, Manitoba, Canada
  • Centre hospitalier de l'Université de Montréal
    Montreal, Quebec H2X 0C1, Canada
  • The Research Institute of the McGill University Health Centre
    Montreal, Quebec H3H 2R9, Canada
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2025 to primary completion in Apr 2026, 10 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 25, 2024
First posted
Aug 1, 2024
StartActual
Jun 12, 2025
Primary completionActual
Apr 15, 2026
CompletionActual
Apr 15, 2026
Last update
Sep 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06533657
Lead sponsor
ZYUS Life Sciences Inc.
Responsible party
Sponsor
First posted
Aug 1, 2024
Start date
Jun 12, 2025
Primary completion
Apr 15, 2026
Completion
Apr 15, 2026
Last update
Sep 1, 2026

Study contacts

Julie Stakiw, MD
study director · Saskatoon Cancer Centre

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dronabinol

Start the discussion